Related Experiment Video

Updated: May 4, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.6K

Underexpressed CNDP2 participates in gastric cancer growth inhibition through activating the MAPK signaling pathway

Zhenwei Zhang1, Lei Miao2, Xiaoming Xin3

  • 1Department of Biochemistry and Molecular Biology, Second Military Medical University, Shanghai, China Key Laboratory of Liver Disease, Center of Infectious Diseases, Guangzhou 458 Hospital, Guangzhou, China.

Molecular Medicine (Cambridge, Mass.)
|January 8, 2014
PubMed

Insights

Cytosolic non-specific dipeptidase 2 (CNDP2) functions as a tumor suppressor in gastric cancer. Restoring CNDP2 inhibits cancer cell growth and activates the MAPK pathway, suggesting therapeutic potential.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Cytosolic non-specific dipeptidase 2 (CNDP2) has emerging roles beyond enzymatic activity, particularly in cancer.
  • The specific function of CNDP2 in gastric cancer pathogenesis is not well understood.

Purpose of the Study:

  • To investigate the role of CNDP2 in gastric cancer.
  • To elucidate the molecular mechanisms underlying CNDP2's function in gastric cancer.

Main Methods:

  • Analysis of CNDP2 expression in gastric cancer tissues.
  • In vitro studies assessing cell proliferation, apoptosis, and cell cycle.
  • In vivo tumor growth assays in nude mice.
  • Western blot analysis to examine MAPK pathway activation (p38, JNK, ERK).

Main Results:

  • CNDP2 expression is frequently downregulated in gastric cancer tissues.
  • Ectopic CNDP2 expression inhibited cell proliferation, induced apoptosis, caused cell cycle arrest, and suppressed tumor growth.
  • CNDP2 reintroduction upregulated p38 and activated JNK, while CNDP2 loss increased ERK phosphorylation.
  • These findings implicate CNDP2 in the modulation of the mitogen-activated protein kinase (MAPK) pathway.

Conclusions:

  • CNDP2 acts as a tumor suppressor in gastric cancer.
  • CNDP2 exerts its tumor-suppressive effects through the activation of the MAPK signaling pathway.
  • Targeting CNDP2 may offer a novel therapeutic strategy for gastric cancer.

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

9.1K
Development of Compendium for Esophageal Squamous Cell Carcinoma03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

974

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.7K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K